We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-18.45%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$122M
AUM Growth
+$7.43M
Cap. Flow
+$13.4M
Cap. Flow %
10.99%
Top 10 Hldgs %
82.45%
Holding
116
New
28
Increased
22
Reduced
30
Closed
27

Top Buys

Rank Stock Value
1
BCLI
BRAINSTORM CELL THERAPUTC
BCLI
+$3.5M
2
PBLA
Panbela Therapeutics, Inc. Common Stock
PBLA
+$2.24M
3
SIDU icon
Sidus Space
SIDU
+$1.75M
4
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
+$1.7M
5
GCTK icon
GlucoTrack
GCTK
+$1.22M

Top Sells

Rank Stock Value
1
APCX
AppTech Payments
APCX
+$1.03M
2
CNEY icon
CN Energy Group
CNEY
+$799K
3
ARDS
Aridis Pharmaceuticals Inc. Common Stock
ARDS
+$672K
4
DOGZ icon
Dogness International Corp
DOGZ
+$543K
5
HUDI icon
Huadi International Group
HUDI
+$528K

Sector Composition

Rank Sector Weight
1 Healthcare 14.59%
2 Consumer Discretionary 2%
3 Industrials 1.44%
4 Financials 1.38%
5 Communication Services 1.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OEF icon
1
PUT
iShares S&P 100 ETF
OEF
$19.8B
$63.8M 52.23%
3,409
+1,417
+71% +$275K
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
$24.9M 20.34%
561
-612
-52% -$257K
BCLI
3
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$2.61M 2.14%
+84,525
New +$3.5M
BIOR
4
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$1.86M 1.52%
+48,261
New +$1.7M
SONN
5
DELISTED
Sonnet BioTherapeutics
SONN
$1.61M 1.32%
18,699
+11,793
+171% +$832K
RVPH
6
CALL
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$1.37M 1.12%
117
+111
+1,850% +$14.1K
AKTX
7
Akari Therapeutics
AKTX
$14.8M
$1.26M 1.03%
9,240
-687
-7% -$99.3K
SIDU icon
8
Sidus Space
SIDU
$172M
$1.16M 0.95%
+64,136
New +$1.75M
ITRM
9
DELISTED
Iterum Therapeutics
ITRM
$1.13M 0.92%
+75,000
New +$83K
RCON icon
10
Recon Technology
RCON
$39.6M
$1.09M 0.89%
175,238
-44,077
-20% -$315K
TC
11
TuanChe
TC
$61M
$996K 0.81%
6,638
-1,517
-19% -$254K
AIOS
12
AIOS Tech
AIOS
$41.1M
$892K 0.73%
12,100
+8,431
+230% +$762K
DOGZ icon
13
Dogness International Corp
DOGZ
$14M
$853K 0.7%
58,456
-34,126
-37% -$543K
GCTK icon
14
GlucoTrack
GCTK
$1.97M
$702K 0.57%
+339
New +$1.22M
NMTR
15
DELISTED
9 Meters Biopharma
NMTR
$698K 0.57%
1,038,440
-65,205
-6% -$57.7K
SHFS icon
16
SHF Holdings
SHFS
$1.25M
$669K 0.55%
63,139
+4,943
+8% +$50.2K
ATXI
17
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
$647K 0.53%
7,378
+3,646
+98% +$300K
MRAI
18
DELISTED
Marpai, Inc. Class A Common Stock
MRAI
$643K 0.53%
+375,968
New +$1.08M
BNKK
19
Bonk Inc
BNKK
$8.32M
$597K 0.49%
40,623
-13,634
-25% -$193K
ENSC icon
20
Ensysce Biosciences
ENSC
$3.86M
$580K 0.47%
+21,487
New +$972K
FRZA
21
DELISTED
Forza X1, Inc. Common Stock
FRZA
$578K 0.47%
+393,411
New +$552K
SNGX icon
22
Soligenix
SNGX
$5.36M
$573K 0.47%
+50,890
New +$884K
RVPH
23
PUT
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$554K 0.45%
47
+31
+194% +$3.93K
BCTXW
24
PUT
DELISTED
BriaCell Therapeutics Corp Warrant
BCTXW
$544K 0.45%
848
-2,380
-74% -$6.56K
PBLA
25
DELISTED
Panbela Therapeutics, Inc. Common Stock
PBLA
$542K 0.44%
11,791
+11,080
+1,558% +$2.24M
1
2 3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2023 Portfolio in Review

As of Q2 2023, Sabby Management held 116 positions worth $122M, up 6.5% from $115M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Sabby Management deployed $13.4M of net new capital in Q2 2023, opening 28 new positions and adding to 22 existing holdings. Its largest new stake was BRAINSTORM CELL THERAPUTC: 84,525 shares worth $2.61M.

By sector, the portfolio is most concentrated in Healthcare at 15% of assets, up from 9.8% a quarter earlier, followed by Consumer Discretionary and Industrials.

On the sell side, the largest reduction was CN Energy Group, an estimated $799K trimmed.

  • Sabby Management's largest Q2 2023 buy was BRAINSTORM CELL THERAPUTC: 84,525 shares worth $2.61M.
  • Sabby Management added most to Panbela Therapeutics, Inc. Common Stock in Q2 2023, an estimated $2.24M increase.
  • Sabby Management's biggest Q2 2023 reduction was CN Energy Group, cutting an estimated $799K.
  • Sabby Management fully exited AppTech Payments in Q2 2023, selling an estimated $1.03M.
  • Sabby Management's ten largest holdings make up 82% of its $122M portfolio in Q2 2023.
  • Sabby Management opened 28 new positions and closed 27 in Q2 2023.
  • Sabby Management's portfolio value rose 6.5% quarter-over-quarter to $122M.

Based on Sabby Management's 13F filing for Q2 2023, filed 14 Aug 2023.